This technology includes a procedure for novel virus identification in a variety of human specimens by solexa high-throughput sequencing, which allows for the screening a large number of clinical specimens for novel virus discovery in a highly efficient and relatively economical method. By using this technique, we have successfully identified a novel parvovirus from samples of seronegative hepatitis patients. In a total of 70 samples tested, nineteen of them (27%) were positive by solexa sequencing and 23 (33%) were positive by PCR, which was developed based on the viral sequences obtained from the solexa data. Based on phylogenetic and genome structure analysis, this newly identified virus represents a new genus of parvoviridae family. This discovery potentially lays a foundation for the development of diagnostic reagents, vaccine and treatment against the viral hepatitis.